论文部分内容阅读
目的探讨甘精胰岛素联合格列美脲及诺和锐30对HbA1c>9%的新诊断T2DM患者血糖波动的影响。方法将46例新诊断的T2DM患者随机分为甘精胰岛素联合格列美脲(IG)组与诺和锐30(AS30)组。IG组予以睡前皮下注射甘精胰岛素联合口服格列美脲治疗12周;AS30组予以诺和锐30于早晚餐时皮下注射12周,对比两组治疗前后血糖谱的变化。结果 IG组与AS30组血糖均得到效控制,但IG组血糖波动小、低血糖事件发生率低、胰岛素用量少(P<0.05)。结论甘精胰岛素联合格列美脲对HbA1c>9%的新诊断T2DM患者是一种更为安全、方便的治疗方案。
Objective To investigate the effects of glargine combined with glimepiride and Novolinol 30 on the blood glucose fluctuation in newly diagnosed T2DM patients with HbA1c> 9%. Methods 46 cases of newly diagnosed T2DM patients were randomly divided into glargine and glimepiride (IG) group and Novo Rui 30 (AS30) group. IG group were given glargine and oral glimepiride at bedtime for 12 weeks. AS30 group was given Novo-Rui-30 for 12 weeks at breakfast and dinner, and the changes of blood glucose spectrum were compared before and after treatment. Results Both IG and AS30 groups were effective in controlling blood glucose. However, IG group had less fluctuation of blood glucose, low incidence of hypoglycaemia and less insulin (P <0.05). Conclusion Glargine and glimepiride are a safer and more convenient treatment for newly diagnosed T2DM patients with HbA1c> 9%.